1 / 9

Prostate Cancer Studies

Prostate Cancer Studies. Mohamed Bidair, M.D. Diplomate, American Board of Urology Alvarado La Mesa Urology Medical Associates Prostate Cancer Research and Education Foundation Featured Speaker Series December 13, 2003. f. Prostate Cancer Studies.

parker
Download Presentation

Prostate Cancer Studies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Prostate Cancer Studies Mohamed Bidair, M.D. Diplomate, American Board of Urology Alvarado La Mesa Urology Medical Associates Prostate Cancer Research and Education Foundation Featured Speaker Series December 13, 2003 f

  2. Prostate Cancer Studies • An investigational selective endothelin receptor antagonist, being developed for the treatment of prostate cancer. These patients must be status-post prostatectomy, hormone naïve, with rising PSA.

  3. Prostate Cancer Studies • Open-Label Leuprolide formulation for patients with prostate cancer in need of chemical castration. A percentage of patients currently on a leuprolide castration regime can be entered in the study if dosing schedule isn’t interupted

  4. Prostate Cancer Studies • A 3 Month Open Label study for patients with advanced prostate cancer curently receiving Lupron or Zoladex versus a new investigational Leuprolide. The study is looking to compare the degree of testosterone suppression, Quality of Life and safety and tolerability between Lupron, Zoladex, and a new agent.

  5. Prostate Cancer Studies • An intravenous bisphosphonate to study the efficacy on the bone mineral density in patients undergoing androgen deprivation therapy for < 1 year. No distant metastasis is required to enter study.

  6. Prostate Cancer Studies • A new oral bisphosphonate to prevent skeletal complications in metatastic prostate cancer patients commencing androgen deprivation therapy.

  7. Prostate Cancer Studies • A new investigational drug, a SERM, to prevent androgen deprivation induced osteoporosis. This compund may also have a direct inhibitory effect on cancer cells, and ameliorate gynecomastia and hot flashes. These patients must have received LHRH treatment > 2 years, PSA < 4, and do not take anti-androgens (Casodex, Eulexin)

  8. Prostate Cancer Studies • An agent being evaluated to reduce the need for transfusion in anemic patients with non-myeloid cancer who are not receiving chemotherapy or radiotherapy.

  9. Prostate Cancer Prevention Study • A study to assess the efficacy and safety of Alpha-Reductase Inhibitor. A 4 year study to reduce the risk of biopsy detectable prostate cancer. Looking for males 50-75 with only one negative biopsy within 6 months of study enrollment. PSA must be between 2.5-10 for males ages 50-60 and between 3-10 for men > 60 years. Must not have had more than one prostate biopsy or any other prostate surgical procedures.

More Related